Back to Search
DAVID AGUS, M.D.
M.D.
Medical Oncology Physician
NPI: 1356328249IndividualAccepts Medicare
Specialties, Licenses & Credentials
Specialist
Specialist
Code: 174400000X
G85631(CA)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
G85631(CA)
Education
PERELMAN SCHOOL OF MED AT THE UNIVERSITY OF PENNSYLVANIA
Class of 1992
Research & Publications (20)
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.
PMID 17308272·J Clin Oncol·2007
3-trial
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.
PMID 15699478·J Clin Oncol·2005
3-trial
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.
PMID 12204533·Cancer Cell·2002
7-preclinical
HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer.
PMID 11236029·Semin Oncol·2000
6-review
Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping.
PMID 18756584·Psychooncology·2009
8-other
The current state of preclinical prostate cancer animal models.
PMID 18213636·Prostate·2008
4-observational
Precursor-ion mass re-estimation improves peptide identification on hybrid instruments.
PMID 18707148·J Proteome Res·2008
8-other
ProteoWizard: open source software for rapid proteomics tools development.
PMID 18606607·Bioinformatics·2008
8-other
A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.
PMID 17662137·BMC Cancer·2007
3-trial
Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer.
PMID 17404077·Clin Cancer Res·2007
7-preclinical
Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
PMID 17317831·Clin Cancer Res·2007
3-trial
Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discovery.
PMID 17147241·Clin Adv Hematol Oncol·2006
8-other
Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial.
PMID 16536755·BJU Int·2006
3-trial
Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies.
PMID 16306877·Br J Cancer·2006
8-other
2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth.
PMID 16265675·Cancer·2005
4-observational
Epithelial membrane protein-1 is a biomarker of gefitinib resistance.
PMID 16087880·Proc Natl Acad Sci U S A·2005
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 12414 EXPOSITION BLVD
LOS ANGELES, CA 90064 - Phone
- (310) 272-7640
Quick Facts
- NPI
- 1356328249
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile